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Abstract
Background: Patients with hematological malignancies are at an increased risk 
of SARS- CoV- 2 disease (COVID- 19) and adverse outcome. However, a low mor-
tality rate has been reported in patients with chronic myeloid leukemia (CML). 
Preclinical evidence suggests that tyrosine kinase inhibitors (TKIs) may have a 
protective role against severe COVID- 19.
Methods: We conducted a cross- sectional study of 564 consecutive patients with 
CML who were tested for anti- SARS- CoV- 2 IgG/IgM antibodies at their first out-
patient visit between May and early November 2020 in five hematologic centers 
representative of three Italian regions.
Results: The estimated serological prevalence of SARS- CoV- 2 infection in 
 patients with CML after the first pandemic wave was similar to that in the general 
population (about 2%), both at national and regional levels. CML patients with 
positive anti- SARS- CoV- 2 serology were more frequently male (p = 0.027) and 
active workers (p = 0.012), while there was no significant association with TKI 
treatment type. Only 3 out of 11 IgG- positive patients had previously received a 
molecular diagnosis of COVID- 19, while the remainders were asymptomatic or 
with mild symptoms.
Conclusions: Our data confirm that the course of SARS- CoV- 2 infection in 
 patients with CML is generally mild and reassure about the safety of continu-
ing TKIs during the COVID- 19 pandemic. Furthermore, we suggest that patients 
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1  |  INTRODUCTION
The clinical course of the 2019 coronavirus (SARS- 
CoV- 2) disease (COVID- 19) is extremely hetero-
geneous, with infected individuals being either 
asymptomatic or developing severe acute respiratory 
manifestations.1  Patients with hematological malig-
nancies are at an increased risk of severe COVID- 19 
and unfavorable outcome.2 However, comparing the 
relative frequencies of hematological disorders ob-
served in COVID- 19 patients seen in March 2020 and 
in patients managed during 2019 at the same hemato-
logical centers revealed that patients with chronic my-
eloproliferative neoplasms, including chronic myeloid 
leukemia (CML) were underrepresented among hospi-
talized patients.3
Imatinib, the first generation tyrosine kinase in-
hibitor (TKI) has dramatically changed the history 
of CML treatment, increasing the rates of molecular 
responses, reducing the likelihood of natural progres-
sion of CML from chronic to advanced phases, and 
improving the survival.4,5 Other BCR- ABL1 inhibitors, 
namely nilotinib, dasatinib, bosutinib, and ponatinib, 
have been subsequently developed to overcome the 
resistance or intolerance to imatinib.6- 9 Still limited 
evidence suggests that some of these drugs may have 
a direct anti- viral action of an indirect effect on the 
host response to SARS- CoV- 2 infection, and ongoing 
trials aim at verifying the effect of TKIs in prevent-
ing pulmonary vascular leak in patients with severe 
COVID- 19 pneumonia.10
To date, the prevalence of SARS- CoV- 2 infection in 
patients with CML has been reported through the collec-
tion of infected cases, as determined by molecular test-
ing on symptomatic individuals and/or contacts through 
qRT- PCR on pharyngeal swabs, and estimating the fre-
quency over the total number of patients followed at 
each center, without direct evaluation of asymptomatic 
patients. The reported prevalence in these studies, con-
ducted during the first months of pandemic, ranged from 
0.17% to 0.9%.11- 15
The seroprevalence of SARS- CoV- 2 infection in a 
cohort of patients with CML, including symptomatic 
and asymptomatic individuals, has not been reported 
yet.
2  |  METHODS
2.1 | Study procedures
In this experimental, cross- sectional, non- pharmacological 
study we enrolled all consecutive patients with CML at-
tending five outpatient hematological centers in three 
Italian regions with different prevalence of infection in 
the general population (Veneto, Friuli- Venezia Giulia, 
and Lazio). The inclusion criteria comprehended an es-
tablished diagnosis of CML according to the World Health 
Organization criteria and age ≥18 years. No exclusion cri-
teria have been envisaged, except for the unwillingness 
to sign a written informed consent. Patients enrolled in 
clinical trials were not excluded unless the participation 
to other experimental, non- pharmacological studies was 
formally precluded by the study protocol. The study was 
approved by local IRBs.
After gathering the information about risk factors for 
COVID- 19 (travels, occupational exposure, living with 
infected individuals) and respiratory or general symp-
toms experienced from mid- February 2020, patients 
were tested for anti- SARS- CoV- 2 IgM and/or IgG anti-
bodies through a qualitative immunochromatographic 
assay (COVID- 19 IgG/IgM Rapid Test Cassette, Menarini 
Diagnostics, IT; sensitivity IgG 97.2%, IgM 87.9%, speci-
ficity IgG/IgM 100%). Patients with positive results un-
derwent a nasopharyngeal swab for molecular detection 
of the virus.
2.2 | Comparison group
The prevalence of SARS- COV- 2 infection in the gen-
eral population was retrieved from the Istat- Italian 
Ministry of Health, SARS- CoV- 2  seroprevalence study, 
which was conducted between May and July 2020 on 
64,660 individuals, and estimated an anti- SARS- CoV- 2 
IgG Italian prevalence of 2.5%, with marked regional 
differences ranging from 0.3% (Sicily and Sardinia) to 
7.5% (Lombardy). As of 15  July 2020 the prevalence of 
SARS- CoV- 2 infection in the three regions involved in 
the present study was 1.9 (95%CI 1.4– 2,5) for Veneto, 
1.0 (95%CI 0.6– 1.5) for Friuli- Venezia Giulia, and 1.0 
(95%CI 0.6– 1.3) for Lazio.16
with CML succeed to mount an antibody response after exposure to SARS- CoV- 2, 
similar to the general population.
K E Y W O R D S
chronic myeloid leukemia, COVID- 19, prevalence, serological tests, TKIs
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2.3 | Statistical analysis
Epidemiological and serological patterns were compared 
using the chi- squared test for differences in terms of cat-
egorical variables (or Fisher's exact test when appropri-
ated), t- test or Mann– Whitney test (when appropriated) 
for difference in terms of continuous variables. For all 
hypotheses tested, two- tailed p values < 0.05 were consid-
ered to be significant.
3  |  RESULTS
3.1 | Study population
From 18  May 2020 to 3  November 2020 a total of 564 
 patients with CML were tested. None refused to partici-
pate. Patients enrolled in ongoing experimental clinical 
trials were all included in the present study since none 
of those study protocols formally precluded the participa-
tion to other experimental, non- pharmacological studies. 
Males were 317 (56%), the median age at study entry was 
63.6 (range 19.6– 93.9) years, and the median time since 
CML diagnosis was 8.6 (range 0.1– 33.7) years.
Sokal risk distribution was 41%, 37%, and 14% for 
L/I/H categories, respectively (8% not available). Nearly 
half of the patients were on the first- line TKI treatment 
(n  =  281, 49.8%), while the remainders were on second 
line (n = 131, 23.2%), third, or further line of treatment 
(n  =  58, 10.3%), or in treatment- free remission (TFR) 
(n = 94, 16.7%).
The type of TKI currently taken was imatinib (n = 205, 
43.6%), nilotinib (n  =  114, 24.1%), dasatinib (n  =  85, 
18.1%), bosutinib (n  =  37, 7.9%), ponatinib (n  =  26, 
5.6%), or experimental (n = 3, 0.7%). The molecular level 
of  response at study entry was MR4.0 or better (n = 356, 
63.1%), MR3.0 (n = 130, 23.1%), MR2.0 (n = 35, 6.2%), or no 
response/recent diagnosis (n = 43, 7.6%).
3.2 | Serological prevalence of SARS- 
CoV- 2 infection
Eleven out of 564 patients had a positive IgG test and 3 of 
them were also IgM- positive, for an estimated serological 
prevalence of SARS- CoV- 2 infection in the CML popula-
tion of 1.95% (95%CI 1.09– 3.46), which was close to the 
national serological prevalence on the general popula-
tion (Table 1). None of them had an active infection at the 
time of study, since all tested negative on the molecular 
nasopharyngeal swab performed immediately after the se-
rological assay. Nine out of these 11 patients came from 
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one from Lazio; the estimated prevalence of infection in 
the three regions was 2.7%, 1%, and 0.8%, respectively, 
which was comparable to the general population also at 
the  regional level.
3.3 | Serological status and modality of 
CML treatment
Eight of the 11 IgG- positive patients were taking TKI 
treatment and 3 were not taking any TKI (i.e., patients in 
TFR) (Figure 1). There was no statistically significant as-
sociation between positive serological test and the type of 
TKI treatment (p = 0.19), nor TFR status (p = 0.40).
3.4 | Serological status and risk factors 
for SARS- CoV- 2 infection
Active workers were 43% of the enrolled patients in the 
entire cohort, and the remainders were retired (42.5%), 
students (0.8%), or unemployed (13.7%). Nineteen, 4, 
and 1 patients reported close contact with COVID- 19 in-
fected individuals at work, at home, or both, respectively.
Patients with positive anti- SARS- CoV- 2 serological test 
were more frequently male (p = 0.027) and active workers 
(p = 0.012). Only three patients were previously diagnosed 
as having COVID- 19, in two cases after close contact with 
infected subjects, while the other patients were asymptom-
atic or with mild symptoms and had not performed any 
diagnostic test for SARS- CoV- 2 before. There was no sta-
tistically significant trend of association between positive 
serological test and contact with indices cases (p = 0.07).
3.5 | Serological status and symptoms
Overall, the frequency of new onset or worsening symp-
toms reported during the last months was as follows: 
anosmia (2.3%), ageusia (1.8%), cough (5.3%), pharyngitis 
(4.3%), dyspnea (3.4%), fever (4.4%), headache (7.8%), as-
thenia (13.1%), arthralgia (13.1%), dizziness (6.2%), nau-
sea/vomiting (2.7%), and diarrhea (4.8%).
The majority of these symptoms correlated with a posi-
tive anti- SARS- CoV- 2 serological test, and anosmia, ageu-
sia, fever, asthenia, and arthralgia had the most significant 
association (Table 2).
4  |  DISCUSSION
The prevalence of SARS- CoV- 2 infection in patients with 
CML has been reported to date through the collection of in-
fected cases, as determined by molecular testing on sympto-
matic individuals, and considering the total of patients with 
CML in charge as the denominator. In the first report from 
F I G U R E  1  Treatment modalities (frequency of each TKI, or TFR status) in the total CML cohort (left panel) and in patients with 
positive anti- SARS- CoV- 2 serological test (right panel)
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the Hubei Province, Li et al described 5 COVID- 19 cases out 
of 530 patients with CML (0.9%), with a higher prevalence in 
advanced CML or in subjects without complete hematologic 
response.11 In a Dutch study, 25% of patients with CML re-
ported mild respiratory symptoms in a self- assessment ques-
tionnaire, but confirmed molecular diagnosis was made in 
only one subject (0.7%).13 A study from Turkey showed that 
ICU admission rates, the need for mechanical ventilation, 
and mortality were lower in COVID- 19 patients with CML 
treated with TKI compared to age, gender, and comorbidity- 
matched control patients without cancer.14 Finally, Breccia 
et al conducted a large survey on the centers belonging to 
the Italian Campus CML program, comprising 6,883 pa-
tients, with a low reported frequency of infection (0.17%) 
and a much higher impact of COVID- 19 pandemic in assur-
ing regular monitoring, TFR strategies, and drug delivery.12
Differently from these studies, we collected comprehen-
sive data on all patients enrolled in this unselected cohort, 
thus being able to compare the characteristics of infected 
and uninfected patients, including the type of TKI treat-
ment. The study was promoted by the University of Verona 
and other two representative Venetian Centers were in-
volved in the project since the Veneto region was one of 
the first areas in which autochthonous COVID- 19 cases 
appeared and rapidly spread at the beginning of pandemic. 
The other two hematologic centers, one in Friuli- Venezia 
Giulia and one in Lazio, were chosen because they were re-
gional reference centers for CML, and the prevalence of the 
infection in those regions during the first pandemic wave 
was different from that of the Veneto region.
The frequency of anti- SARS- CoV- 2 positive patients 
taking nilotinib was numerically higher than that of cases 
treated with other TKIs (Figure 1), but the difference did 
not reach statistical significance. Similarly, the percentage 
of IgG positive patients was higher in TFR (3.1%) than in 
TKI- treated patients (1.7%), but the difference was not sta-
tistically significant.
In vitro studies and limited clinical evidence suggest 
that TKIs may have a direct antiviral action and/or indirect 
immunomodulatory effect.10 Imatinib and nilotinib were 
shown to prevent the fusion of SARS- CoV and MERS- CoV 
Spike (S)- protein with the human epithelial cell membrane 
via Abl- mediated cytoskeletal rearrangement.17 In addition, 
TKIs have been claimed to counteract viral growth through 
the inhibition of Abl2, a cell protein required for viral rep-
lication.18 Other putative anti- coronavirus mechanisms of 
TKIs include improvement of pulmonary endothelial bar-
rier dysfunction in acute lung injury,19 and an immunomod-
ulatory role that may be protective against cytokine storm 
associated with advanced COVID- 19 infection.20 Consistent 
with these preclinical observations, the reported outcome 
of COVID- 19 infection in patients with CML was generally 
mild.3,14,21 Also in the present work, the majority of patients 
with CML had no or mild symptoms, and were not deemed 
worthy of screening during the first pandemic phase, when 
the  access to molecular diagnostic tests was subjected to 
quota. On the other hand, to estimate the actual prevalence 
of anti- SARS- CoV- 2 antibodies in the entire CML popula-
tion, we did not exclude from the study patients previously 
diagnosed as having COVID- 19 infection, and in all these 
three cases, our test confirmed the IgG- positive status, as 
early as 3 weeks after the molecular diagnosis of infection.
The question remains whether TKI might prevent the 
infection by antagonizing the fusion of S- protein with the 
cell membrane, or by inhibiting the intracellular replica-
tion of the virus, or they simply reduce the overproduction 
status
Symptom








Anosmia 5 (45.5) 8 (1.5) <0.001
Ageusia 5 (45.5) 5 (0.9) <0.001
Cough 3 (27.3) 27 (4.9) 0.017
Pharyngitis 2 (18.2) 22 (4.0) 0.075
Dyspnea 0 19 (3.4) ns
Fever 4 (36.4) 21 (3.8) <0.001
Headache 2 (18.2) 42 (7.6) 0.21
Asthenia 5 (45.5) 69 (12.5) 0.008
Arthralgia 5 (45.5) 69 (12.5) 0.008
Dizziness 4 (36.4) 31 (5.6) 0.003
Nausea/vomiting 0 15 (2.7) ns
Diarrhea 1 (9.1) 26 (4.7) 0.42
T A B L E  2  Correlation of new onset 
or worsening symptoms and serological 
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of inflammatory cytokines, which are ultimately respon-
sible for organ failure. Due to the limited number of sub-
jects exposed to SARS- CoV- 2 in the general population 
after the first pandemic wave, in the present study we 
could not demonstrate a preventive role of TKI against in-
fection. However, when limiting the analysis to the period 
(May– July) considered by the ISTAT study on Italian pop-
ulation, the prevalence on patients with CML appeared to 
be lower (1.06%). Instead, a contribution toward a milder 
course of the infection can be assumed due to the absence 
of seriously ill patients. Further studies are needed to ulti-
mately define the TKI contribution against SARS- CoV- 2, 
by comparing on a larger number of cases the seropreva-
lence of SARS- CoV- 2 infection in patients with CML on 
TKI treatment and those in TFR.
We acknowledge the use of a rapid test as a potential 
limitation. However, rapid tests have been developed to 
allow extensive testing in conditions where venipuncture 
and lab infrastructures are not easily available, as happens 
during a pandemic. We also recognize that the choice of 
a single study center for the Friuli- Venezia Giulia and 
Lazio regions may limit the generalization of our findings. 
However, these centers of reference for CML manage a 
high number of patients, and the comparison with the 
data of the Istat survey, which sampled around 0.1% of the 
entire Italian population, is legitimate.
Overall, our data show that prevalence of anti- SARS- 
CoV- 2 IgM and/or IgG positivity in patients with CML 
was comparable to the general population in the same 
period both at national and regional levels, and reassure 
about the safety of continuing TKI treatment in patients 
with CML during the ongoing SARS- CoV- 2 pandemic. 
Furthermore, our data suggest that patients with CML, 
whether on TKI treatment or not, are able to mount an 
antibody response after exposure to SARS- CoV- 2. This 
observation might imply that in patients with CML the 
efficiency of vaccination against SARS- CoV- 2 could be 
similar to that of the general population, but this hypothe-
sis needs to be confirmed by future research.
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